NCT06549959招募中1 期
An Open-label, Randomized, Parallel Group, Single Dose Study to Investigate the Pharmacokinetics of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 248
- 试验地点
- 3
- 主要终点
- C-max
研究概览
简要总结
This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to evaluate the Pharmacokinetics and safety of Telitacicept Pre-filled Injection and Freeze-dried powder Injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18-50 years old at the time of signing the informed consent form，gender is unlimited；
- •Male Weight 55-70 kg, female Weight 50-65 kg, and BMI ranging from 18 to 28 kg/m2 (including critical values);
- •Physical examination, vital signs, chest radiographs, ECG, epidemiologic tests, routine blood tests, blood biochemistry, lipids, urinalysis, and coagulation are normal，or abnormal by the investigator as having no clinical significance；
- •Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent, and be able to complete all trial procedures according to the trial requirements.
排除标准
- •Site staff and family members directly involved in the trial; or sponsor staff and family members directly involved in the implementation of the trial;
- •History of any of any nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood and lymphatic system, skeletal muscle system, immune system, metabolic system disease, or other diseases that are not suitable for clinical trials (such as mental history, malignant tumors, etc.);
- •History of lymphoproliferative disease (e.g., EB virus associated lymphoproliferative disease), lymphoma, leukemia, myeloproliferative disease, multiple myeloma, or signs and symptoms suggestive of lymphoproliferative disease;
- •History of abnormal bleeding or coagulation disorders (such as prone to bruising, gingival bleeding, prolonged bleeding after tooth extraction, joint hemorrhage, heavy menstruation leading to anemia within 1 year, postpartum hemorrhage, vitamin K deficiency, hemorrhagic disease caused by acquired coagulation factor antibodies, bleeding after trauma or surgery, etc.) , or abnormal laboratory coagulation parameters, or an inherited tendency to bleed or have coagulation dysfunction, or have a history of blood clots or bleeding, or require long-term use of anticoagulants or antiplatelet aggregation drugs;
- •During screening, 12-lead ECG showing QTcF≥450 ms in male or QTcF≥470 ms in female, or the presence of degree II/III atrioventricular block, or other clinically significant ECG abnormalities are judged by investigators not inappropriate;
- •The first-degree relatives of the subject had inherited immunodeficiency;
- •Current allergic disease, or history of allergy to therapeutic or diagnostic protein products ,allergy to alcohol(alcohol is used to sterilize injection sites), or allergy to two or more drugs and/or non-drug factors;
- •Surgery within 6 months prior to screening, or planned surgery during the trial, or within 2 weeks of the end of the trial(including cosmetic surgery, dental surgery, oral surgery, etc.);
- •Participation in a clinical trial of another drug within 3 months prior to screening;
- •Use of drugs that inhibit or induce hepatic metabolism within 4 weeks prior to randomization or need for use during the trial(e.g., inducers--barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors--SSRI antidepressants, cimetidine, Diltiazem macrolides, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines);
- •Current use of any prescription or over-the-counter (herbal, vitamins, or healthcare products). Current use is defined as use within 14 days or PK equivalent of 5 half-lives prior to randomization, whichever is longer;
- •History of Bleeding or donated more than 100ml blood 3 months before screening period, or plan to denote blood within 1 month after the trial;
- •Positive breath test results for alcohol or alcoholism in the 6 months prior to the screening period(≥14 units of alcohol per week: one standard unit contains 14g of alcohol, equals to 360ml of beer, 45ml of 40% liquor or 150ml of wine), or unable to stop drinking during the trial;
- •More than 5 cigarettes per day within 6 months prior to screening , or unable to quit smoking during the trial;
- •Consume excessive caffeine-containing beverages, foods that may affect drug metabolism within four weeks prior to screening: coffee (≥1100 mL per day), tea (≥2200 mL per day), cola (≥2200 mL per day), energy drinks (≥1100 mL per day), chocolate (≥510 g per day);
- •History of drug abuse, drug dependence, or drug use within 5 years prior to screening；
- •Subject may use weight-loss medications, or excessive dieting, or overeating during the trial;
- •Tattoos, scarring, or other conditions in the planned injection site area (front of thigh) that may interfere with the evaluation of the injection site;
- •COVID-19 vaccine within 2 weeks prior to randomization，or live vaccine within 30 days prior to randomization， or live vaccine required during the trial;
- •Positive test for Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, Treponema pallidum antibody, tuberculin test (IGRAs);
- •History of any clinically significant infections within 6 months prior to screening (e. g., requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections);
- •History of symptomatic herpes zoster or herpes simplex, more than one episode of localized herpes zoster, or disseminated herpes zoster (single episode) within 12 weeks prior to screening；
- •Female subjects with a positive pregnancy test during screening period，or lactating female ; subjects and their partners do not agree to take effective contraceptive measures (such as intrauterine devices, contraceptives or condoms) throughout the trial and within 4 months after injection of the Investigational drug;
- •Investigators believe that there are other factors that are not suitable for participating in the experiment.
研究组 & 干预措施
Telitacicept Pre-filled Injection 80mg
Experimental
干预措施: Telitacicept Pre-filled Injection 80mg (Drug)
Telitacicept Freeze-dried powder Injection 80mg
Experimental
干预措施: Telitacicept Freeze-dried powder Injection 80mg (Drug)
结局指标
主要结局
C-max
时间窗: Day 0#Day 1#Day 2#Day 3#Day 5#Day 8#Day 15#Day 22#Day 29#Day 43#Day 57
Maximum observed plasma concentration
AUC0-∞
时间窗: Day 0#Day 1#Day 2#Day 3#Day 5#Day 8#Day 15#Day 22#Day 29#Day 43#Day 57
Area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration
次要结局
- T-max(Day 0#Day 1#Day 2#Day 3#Day 5#Day 8#Day 15#Day 22#Day 29#Day 43#Day 57)
- Evaluation of AEs (adverse events)(Up to Day 57)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy SubjectsSystemic Lupus ErythematosusNCT04136145GlaxoSmithKline36
已完成
1 期
Japanese phase1 Study of Belimumab (IV vs SC)Systemic Lupus ErythematosusNCT01516450GlaxoSmithKline16
已完成
1 期
A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery SystemHealthy Male SubjectsNCT05275010Hoffmann-La Roche151
已完成
1 期
A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injectorHealth VolunteerNCT06732973Shanghai Junshi Bioscience Co., Ltd.272
已完成
1 期
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderPsychotic DisordersMood DisordersSchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersMental DisordersAntipsychotic AgentsTranquilizing AgentsCentral Nervous System DepressionPhysiological Effects of DrugsPsychotropic DrugsNeurotransmitter AgentsMolecular Mechanisms of Pharmacological ActionNCT05321602Luye Pharma Group Ltd.89